EcoDrugPlus


Keyword(s):	Human Metabolites
Molecule Category	Free-form
EPA CompTox	DTXSID30928041

Keyword(s):

Human Metabolites

Molecule Category

Free-form

EPA CompTox

DTXSID30928041


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70


InChI Key	SYDYRFPJJJPJFE-UHFFFAOYSA-N
Smiles	OCNC=1N=C(N=C(N1)N(CO)CO)N(CO)CO
InChI	InChI=1/C8H16N6O5/c15-1-9-6-10-7(13(2-16)3-17)12-8(11-6)14(4-18)5-19/h15-19H,1-5H2,(H,9,10,11,12)

InChI Key

SYDYRFPJJJPJFE-UHFFFAOYSA-N

Smiles

OCNC=1N=C(N=C(N1)N(CO)CO)N(CO)CO

InChI

InChI=1/C8H16N6O5/c15-1-9-6-10-7(13(2-16)3-17)12-8(11-6)14(4-18)5-19/h15-19H,1-5H2,(H,9,10,11,12)

Property Name	Value
Molecular Formula	C8H16N6O5
Molecular Weight	276.12
AlogP	-3.93
Hydrogen Bond Acceptor	10.0
Hydrogen Bond Donor	6.0
Number of Rotational Bond	7.0
Polar Surface Area	161.56
Molecular species	None
Aromatic Rings	1.0
Heavy Atoms	19.0

Property Name

Value

Molecular Formula

C8H16N6O5

Molecular Weight

276.12

AlogP

-3.93

Hydrogen Bond Acceptor

10.0

Hydrogen Bond Donor

6.0

Number of Rotational Bond

7.0

Polar Surface Area

161.56

Molecular species

None

Aromatic Rings

1.0

Heavy Atoms

19.0

Resources	Reference
CAS NUMBER	13329-69-6
NORMAN SUSDAT
PubChem	83347

Resources

Reference

CAS NUMBER

13329-69-6

NORMAN SUSDAT

PubChem

83347


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

[[6-[(HYDROXYMETHYL)AMINO]-1,3,5-TRIAZINE-2,4-DIYL]DINITRILO]TETRAKISMETHANOL

Structure

Physicochemical Descriptors

Cross References